Is 6996.HK overvalued or undervalued?

6996.HK currently has a P/E ratio of 34.01. Relative to the sector average of 26.80, this suggests the stock may be overvalued. A higher P/E than peers means investors are paying more for each unit of earnings, often because they expect faster future growth. However, if that growth does not materialize, the stock can appear overvalued. A lower P/E may indicate weaker growth expectations or higher risk, but it can also signal a potential valuation discount.

How can I buy Antengene Corporation Limited stock?

Antengene Corporation Limited trades on HKSE. Investors in Latin America can buy it through international and regional brokerage and investment platforms. You simply need a valid government ID or passport to get started.

Can I buy fractional shares of 6996.HK?

Yes. Through fractional investing, you can invest exactly the amount you want, starting with as little as $1 or $5 USD (depending on what investment platform you use), and own a proportional piece of the company.

Does buying 6996.HK protect my money against local inflation?

Many investors in Latin America buy international stocks like 6996.HK to protect their purchasing power. Because 6996.HK is priced in foreign currency, your investment is tied to a hard currency. If your local currency devalues against the foreign currency, usually USD or Euro, the underlying value of your stock portfolio remains protected from local inflation.

Do I need a foreign bank account or a Visa to buy 6996.HK shares?

No. A common misconception is that you need a foreign bank account or a foreign visa to invest in international stocks. Today, modern investment platforms allow you to fund your account using local bank transfers or local payment methods right from your home country.

Is 6996.HK a suitable investment for my portfolio?

There is no universal answer, since fit depends on your situation, not just the stock. Think about three things: how well 6996.HK diversifies what you already own, whether you can stomach its price swings given your risk tolerance, and how long you plan to stay invested. As a rule, a single stock works best as one piece of a broader asset allocation and with a multi-year time horizon. This is general information, not personalized financial advice.

All stocks6996.HK

Antengene Corporation Limited

HK$3.19-HK$0.12-3.63%

HKSE / HKD

Market cap

HK$2.2B

P/E

34.0

EPS (TTM)

HK$0.01

Dividend yield

0.00%

Beta

0.37

1Y return

-48.38%

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Compare, tap a companyup to 2 at once

Deposit US$200 and get US$50 for freeT&C apply. Your capital is at risk.Invest with

Financials

The numbers behind the company

Revenue vs net income

RevenueNet income

$5M2021

$23M2022

$9M2023

$13M2024

$15M2025

Financial health

Gross margin

Operating margin

ROE

ROA

Debt to equity0.28Low
Current ratio4.95
Cash ratio3.62
Net margin9.1%
Free cash flow—

Valuation

Is it expensive right now

P/E vs the market

scale 0–50

0153050

6996.HK34.0
Healthcare sector median26.8
S&P 50022.0

Trades about 27% above its sector, the market expects faster growth.

Ratios

PEG0.31
Price to book1.88
EPS (TTM)HK$0.01
Payout ratio0%
FCF yield-8.39%

Range & risk

HK$2.76HK$6.41

Trading in the lower third of its 52-week band

Beta0.37

Profile

What Antengene Corporation Limited actually does

Antengene Corporation Limited, a biopharmaceutical firm, is dedicated to developing advanced oncology treatments primarily within the Chinese market. Its active clinical development pipeline includes several innovative compounds. Among these, ATG-016, a next-generation XPO1 inhibitor, is currently undergoing Phase I/II clinical trials for individuals with solid tumors. ATG-527 (Verdinexor) has successfully completed its Phase I evaluation for chronic human viral infections. The company is also advancing ATG-019, a dual PAK4/NAMPT inhibitor targeting non-Hodgkin's lymphoma and advanced solid tumors, and ATG-017, an ERK1/2 inhibitor designed for treating advanced solid tumors and hematologic malignancies. Additionally, ATG-010 (selinexor) is a SINE compound that modulates XPO1. ATG-101, a bispecific PD-L1/4-1BB antibody, is in Phase I studies for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma. Completing its clinical-stage assets is ATG-008 (onatasertib), an orally delivered mTOR kinase inhibitor aimed at solid tumors exhibiting specific genetic alterations like NFE2L2, STK11, and RICTOR. In its earlier, pre-clinical research phase, Antengene is exploring ATG-037, a CD73 inhibitor for advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; ATG-031, a CD24 antibody; ATG-027, a B7H3/PD-L1 bispecific antibody; ATG-032, a LILRB antibody; and ATG-041, an Axl-Mer inhibitor. Founded in 2016, the company maintains its headquarters in Shanghai, China.

CEO

Jay Mei

Employees

122

Headquarters

Shanghai, SH

Founded

2020-11-20

Company website

If you had invested a decade ago

Loading the full price history…

Run your own numbers

Past performance is not a forecast.

ETFs

Own it inside an ETF instead

Vanguard S&P 500

Vanguard Total Stock Market

Vanguard Total World Stock

Invesco QQQ

SPDR S&P 500

iShares Russell 2000

Community sentiment

Bullish—

Distribution

Bearish0%
Neutral0%
Bullish0%

Track it without buyingTrack it

no account needed

Save 6996.HK and get told when something moves.

Get updates

A clear, direct weekly summary.

Keep looking

Q&A

Questions people ask

6996.HK has a beta of 0.37, which indicates how sensitive it has historically been to movements in its broader market. A beta below 1 indicates lower relative volatility than the market. Beta is based on historical data and does not predict future performance.

Antengene Corporation Limited